收稿日期: 2019-07-09
网络出版日期: 2019-08-25
基金资助
上海市卫生和计划生育委员会科研课题(201640231)
陈平, 吴云林 . 胃癌、结肠直肠癌血清标志物在疾病筛查、诊断中的应用新进展[J]. 诊断学理论与实践, 2019 , 18(04) : 377 -382 . DOI: 10.16150/j.1671-2870.2019.04.001
| [1] | Suenaga Y, Kanda M, Ito S, et al. Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer[J]. World J Gastrointest Oncol, 2019, 11(1):17-27. |
| [2] | Jia J, Zhang P, Gou M, et al. The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer[J]. Dis Markers, 2019, 2019:6812045. |
| [3] | Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death[J]. Aust Med J, 1869, 14:146. |
| [4] | Arigami T, Uenosono Y, Yanagita S, et al. Clinical significance of circulating tumor cells in blood from patients with gastric cancer[J]. Ann Gastroenterol Surg, 2017, 1(1):60-68. |
| [5] | Liu JL, Gao W, Kang QM, et al. Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis[J]. PLoS One, 2013, 8(8):e71930. |
| [6] | Yie SM, Lou B, Ye SR, et al. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse[J]. Ann Surg Oncol, 2008, 15(11):3073-3082. |
| [7] | Bertazza L, Mocellin S, Marchet A, et al. Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival[J]. J Transl Med, 2009, 7:111. |
| [8] | Arigami T, Uenosono Y, Hirata M, et al. Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis[J]. J Surg Oncol, 2010, 102(7):748-752. |
| [9] | Huang MY, Tsai HL, Huang JJ, et al. Clinical Implications and Future Perspectives of Circulating Tumor Cells and Biomarkers in Clinical Outcomes of Colorectal Cancer[J]. Transl Oncol, 2016, 9(4):340-347. |
| [10] | Yamamoto S, Shimizu K, Fei J, et al. Ex vivo culture of circulating tumor cells using magnetic force-based coculture on a fibroblast feeder layer[J]. Biotechnol J, 2016, 11(11):1433-1442. |
| [11] | Emami SS, Nekouian R, Akbari A, et al. Evaluation of circulating miR-21 and miR-222 as diagnostic biomarkers for gastric cancer[J]. J Cancer Res Ther, 2019, 15(1):115-119. |
| [12] | Necula L, Matei L, Dragu D, et al. Recent advances in gastric cancer early diagnosis[J]. World J Gastroenterol, 2019, 25(17):2029-2044. |
| [13] | Roh MS, Lee HW, Jung SB, et al. Expression of miR-200c and its clinicopathological significance in patients with colorectal cancer[J]. Pathol Res Pract, 2018, 214(3):350-355. |
| [14] | Wu Y, Song Y, Xiong Y, et al. MicroRNA-21 (Mir-21) Promotes Cell Growth and Invasion by Repressing Tumor Suppressor PTEN in Colorectal Cancer[J]. Cell Physiol Biochem, 2017, 43(3):945-958. |
| [15] | Fukushima Y, Iinuma H, Tsukamoto M, et al. Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer[J]. Oncol Rep, 2015, 33(2):573-582. |
| [16] | Hollis M, Nair K, Vyas A, et al. MicroRNAs potential utility in colon cancer: Early detection, prognosis, and chemosensitivity[J]. World J Gastroenterol, 2015, 21(27):8284-8292. |
| [17] | Sanger HL, Klotz G, Riesner D, et al. Viroids are single-stranded covalently closed circular RNA molecules exis-ting as highly base-paired rod-like structures[J]. Proc Natl Acad Sci U S A, 1976, 73(11):3852-3856. |
| [18] | Li P, Chen S, Chen H, et al. Using circular RNA as a novel type of biomarker in the screening of gastric cancer[J]. Clin Chim Acta, 2015, 444:132-136. |
| [19] | Sun H, Tang W, Rong D, et al. Hsa_circ_0000520, a potential new circular RNA biomarker, is involved in gastric carcinoma[J]. Cancer Biomark, 2018 Feb 6; 21(2):299-306. |
| [20] | Shi P, Wan J, Song H, et al. The emerging role of circular RNAs in gastric cancer[J]. Am J Cancer Res, 2018, 8(10):1919-1932. |
| [21] | Lei B, Tian Z, Fan W, et al. Circular RNA: a novel biomarker and therapeutic target for human cancers[J]. Int J Med Sci, 2019, 16(2):292-301. |
| [22] | Weng W, Wei Q, Toden S, et al. Circular RNA ciRS-7-A Promising Prognostic Biomarker and a Potential Therapeutic Target in Colorectal Cancer[J]. Clin Cancer Res, 2017, 23(14):3918-3928. |
| [23] | Shahjehan F, Kamatham S, Kasi PM. Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018[J]. Front Oncol, 2019, 9:358. |
| [24] | Fang WL, Lan YT, Huang KH, et al. Clinical significance of circulating plasma DNA in gastric cancer[J]. Int J Cancer, 2016, 138(12):2974-2983. |
| [25] | Hu Y, Guo H, Chen Y, et al. The mutational landscape of circulating cell free DNA in patients with colorectal adenoma and carcinoma[J]. J Clin Oncol, 2018, 36(15_suppl):e15662. |
| [26] | Kim K, Shin DG, Park MK, et al. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection[J]. Ann Surg Treat Res, 2014, 86(3):136-142. |
| [27] | Kehagias P, Vandeputte C, Ameye L, et al. High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib[J]. J Clin Oncol, 2018, 36 (15_suppl):3532. |
| [28] | Murray DH, Symonds EL, Young GP, et al. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival[J]. J Cancer Res Clin Oncol, 2018, 144(9):1741-1750. |
| [29] | Sánchez-Zauco N, Torres J, Gómez A, et al. Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study[J]. BMC Cancer, 2017, 17(1):384. |
| [30] | Vainer N, Dehlendorff C, Johansen JS. Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer[J]. Oncotarget, 2018, 9(51):29820-29841. |
| [31] | Hong JT, Son DJ, Lee CK, et al. Interleukin 32, inflammation and cancer[J]. Pharmacol Ther, 2017, 174:127-137. |
| [32] | Liu Y, Yao J. Research progress of cystatin SN in cancer[J]. Onco Targets Ther, 2019, 12:3411-3419. |
/
| 〈 |
|
〉 |
